Establishment Labs Q2 revenue $44.1M, loss narrows; FDA PMA inspection completed

ESTABLISHMENT LABS HOLDINGS INC.

2024-Q2 EPS reported -$1.21 revenue$81,284,000

Q2 revenue $44.1M vs $48.6M YoY; gross margin improved to 65.6% from 62.3%.
Operating loss $9.3M vs $13.7M loss YoY; adjusted EBITDA loss $4.3M vs $9.3M.
Net loss $17.2M; cash $54.6M, up $14.6M from Dec 2023.
FY2024 revenue guidance reaffirmed $174M-$184M (+5-11% YoY).
FDA completed PMA preapproval inspection July 26; Motiva Implants US approval expected soon.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.